The weekly litigation news digest is live. Subscribe now

Biogen Idec Ma competitive analysis

Loading summary...

Explore Biogen Idec Ma's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Nov 13, 2025
Patent NumberPublication DateTitleTotal Oppositions
Mar 26, 2025Methods Of Preventing And Removing Trisulfide Bonds3
Oct 2, 2024Methods And Products For Evaluating An Immune Response To A Therapeutic Agent1
Oct 18, 2023A Limiter For A Dispensing Device2
Aug 24, 2022Compositions And Uses For Treating Multiple Sclerosis15
Jun 29, 2022Cell Line Expressing Single Chain Factor Viii Polypeptides And Uses Thereof2
Aug 14, 2019Methods Of Treating Inflammatory And Autoimmune Diseases With Natalizumab1
Apr 24, 2019Method Of Assessing Risk Of Pml1
Apr 18, 2018Methods Of Preventing And Removing Trisulfide Bonds2
Dec 20, 2017Methods Of Treating Inflammatory And Autoimmune Diseases With Natalizumab1
Nov 29, 2017Assay For Jc Virus Antibodies1

Latest PTAB cases involving Biogen Idec Ma

Discover the latest PTAB cases involving Biogen Idec Ma, highlighting their recent legal challenges and patent disputes.

Last updated on: Nov 16, 2025
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Biogen Idec Ma

IPR2015-01993Sep 28, 2015COALITION FOR AFFORDABLE DRUGS VBIOGEN IDEC MAFinal Written Decision

Peer Comparison New

IP litigation analysis comparing Biogen Idec Ma with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Nov 13, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
BIOGEN IDEC MA - 30 - 1
HEXAL573 - -
PHARMACEUTICAL WORKS POLPHARMA3 - - -
POLPHARMA BIOLOGICS9 - - -